Nav: Home

Testosterone therapy provides protection against cardiovascular disease in men with low testosterone

February 13, 2017

(Boston)--Despite the continued controversy surrounding the use of testosterone in men who have testosterone deficiency (hypogonadism), a new study has found that long-term use of testosterone therapy not only improves vigor and vitality, but may reduce the risk of death due to cardiovascular (CV) disease.

These findings appear online in the Journal of Cardiovascular Pharmacology and Therapeutics.

Testosterone (T) is the primary male sex hormone. In men, T plays a key role in the development of male reproductive tissues as well as promoting secondary sexual characteristics such as increased muscle and bone mass and growth of body hair. In addition, T is essential for overall health and well-being and for the prevention of osteoporosis. Insufficient levels of circulating T in men, contributes to frailty and bone loss.

In the absence of large, prospective, placebo-controlled clinical trials of longer duration, substantial evidence regarding the safety and risk of testosterone therapy (TTh) with regard to cardiovascular outcomes can only be gleaned from observational studies. To date, there are limited studies comparing the effects of long-term TTh in hypogonadal men who were treated or remained untreated with T.

Researchers at Boston University Schools of Medicine (BUSM) and Public Health (BUSPH), along with researchers in Germany, established a registry to assess long-term effectiveness and safety of T in men. For this study, they sought to compare its effects on a host of parameters (obesity, cholesterol levels, diabetes, liver function) considered to contribute to cardiovascular disease.

The researchers followed a group of men for eight years who had been on TTh and compared them with another group of men who remained untreated for the same time period. They found there were only two deaths in the TTh group and neither was related to CV events. In the non-treated control group, there were 21 deaths, 19 of which were related to CV events. Furthermore, there were 26 non-fatal myocardial infarctions and 30 non-fatal strokes in the control group but none in the T-treated group.

According to the researchers, long-term TTh in men with hypogonadism appears to be an effective approach to achieve sustained improvements in cardiometabolic function and reduces the risk of CV events. "The low CV events observed in the T-group compared to the untreated (control) group strongly suggest that TTh is protective. We believe that the protective effect of T on the CV system provides clinicians with the opportunity to utilize this approach for secondary prevention for hypogonadal men with a history of CV events," explained corresponding author Abdulmaged M. Traish, PhD, professor of biochemistry and urology at BUSM.
-end-
Conflict of interest disclosure statement:

Contributing authors Dr. Farid Saad is a full time employee of Bayer Pharma.
Dr. Ahmad Haider has received partial compensation for data entry from Bayer Pharma.
Dr. Gheorghe Doros has received payment for statistical analysis from Bayer Pharma.

Boston University Medical Center

Related Testosterone Articles:

Testosterone makes men less likely to question their impulses
A new study shows that testosterone makes men less likely to realize when they're wrong.
Testosterone treatments may increase cardiac risks
A new JAMA study found a 20 percent increase in arterial plaque among men aged 65 and older who received testosterone replacement therapy for a year,
Benefits of testosterone therapy in older men are mixed
Older men with low testosterone levels showed improved bone density and strength, as well as reduced anemia, after one year of testosterone therapy, according to a new study conducted at Yale and other sites.
Testosterone therapy provides protection against cardiovascular disease in men with low testosterone
Despite the continued controversy surrounding the use of testosterone in men who have testosterone deficiency (hypogonadism), a new study has found that long-term use of testosterone therapy not only improves vigor and vitality, but may reduce the risk of death due to cardiovascular (CV) disease.
Enzyme that digests vitamin A also may regulate testosterone levels
Bco1, an enzyme that metabolizes beta carotene, may play a vital role in testosterone metabolism as well, according to a new study led by researchers at the University of Illinois.
'Mean girl' meerkats can make twice as much testosterone as males
Testosterone. It's often lauded as the hormone that makes males bigger, bolder, stronger.
Experts take strong stance on testosterone deficiency and treatment
In an effort to address widespread concerns related to testosterone deficiency (TD) and its treatment with testosterone therapy, a group of international experts has developed a set of resolutions and conclusions to provide clarity for physicians and patients.
Scientists develop recipe for testosterone-producing cells
Researchers led by teams at the Johns Hopkins Bloomberg School of Public Health and Wenzhou Medical University of China have discovered a way to keep adult stem cells that are destined to become testosterone-producing cells multiplying and on track to fulfill their fate, a new study reports.
Testosterone therapy decreases hospital readmissions in older men with low testosterone
A new large-scale population-based study from The University of Texas Medical Branch at Galveston showed for the first time that older men using testosterone therapy were less likely to have complications that require them to go back to the hospital within a month of being discharged than men not using this therapy.
Researchers: Testosterone treatment effective for older men
As men age, their sexual function, vitality and strength can decline, but researchers had not yet established whether testosterone treatment is actually beneficial.

Related Testosterone Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Digital Manipulation
Technology has reshaped our lives in amazing ways. But at what cost? This hour, TED speakers reveal how what we see, read, believe — even how we vote — can be manipulated by the technology we use. Guests include journalist Carole Cadwalladr, consumer advocate Finn Myrstad, writer and marketing professor Scott Galloway, behavioral designer Nir Eyal, and computer graphics researcher Doug Roble.
Now Playing: Science for the People

#530 Why Aren't We Dead Yet?
We only notice our immune systems when they aren't working properly, or when they're under attack. How does our immune system understand what bits of us are us, and what bits are invading germs and viruses? How different are human immune systems from the immune systems of other creatures? And is the immune system so often the target of sketchy medical advice? Those questions and more, this week in our conversation with author Idan Ben-Barak about his book "Why Aren't We Dead Yet?: The Survivor’s Guide to the Immune System".